Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

LQDA

+ Watchlist+ Portfolio

Liquidia Corp.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$56.73
52-Week Range
$22.31 – $93.61
Market Cap
$5.08B
P/E (TTM)
—
EPS (TTM)
-1.05
Dividend Yield
0.00%
Advanced Metrics
Price/Book
—
PEG Ratio
—
Return on Equity
—
Return on Assets
38.20%
Gross Margin
92.73%
Operating Margin
47.12%
Profit Margin
-15.15%
Current Ratio
1.02
Debt/Equity
—
Total Debt
$168.76M
Free Cash Flow
$535.60M
Revenue Growth
314.60%
Earnings Growth
—
Enterprise Value
$4.85B

Market Snapshot

About

Liquidia Corp. is a biopharmaceutical company focused on the development and commercialization of therapies for pulmonary arterial hypertension and other respiratory diseases. The company uses proprietary PRINT technology to design and manufacture precisely engineered drug particles. Liquidia is advancing treatments that aim to improve outcomes for patients with cardiopulmonary conditions.